Clinical Trial Update: HLA-Mismatched Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematological Malignancies [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating HLA-mismatched peripheral blood stem cell transplantation for hematologic malignancies has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Myelodysplastic Syndromes
• Myeloid Leukemia

Snippet

Sponsor: National Heart, Lung, and Blood Institute (NHLBI) | Conditions: Graft vs Host Disease, Hematologic Neoplasms | Phase 1 | Status: COMPLETED